"Fluorescein Angiography" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Visualization of a vascular system after intravenous injection of a fluorescein solution. The images may be photographed or televised. It is used especially in studying the retinal and uveal vasculature.
| Descriptor ID |
D005451
|
| MeSH Number(s) |
E01.370.370.050.350 E01.370.380.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluorescein Angiography".
Below are MeSH descriptors whose meaning is more specific than "Fluorescein Angiography".
This graph shows the total number of publications written about "Fluorescein Angiography" by people in this website by year, and whether "Fluorescein Angiography" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 5 | 5 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 4 | 5 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorescein Angiography" by people in Profiles.
-
Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial. Ophthalmology. 2026 Apr; 133(4):451-465.
-
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study. Graefes Arch Clin Exp Ophthalmol. 2026 Feb; 264(2):407-416.
-
Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study?- MICRoN report number four. Graefes Arch Clin Exp Ophthalmol. 2026 Jan; 264(1):73-80.
-
Consideration of patient phenotypes in geographic atrophy due to age-related macular degeneration. BMJ Open Ophthalmol. 2025 Jul 07; 10(1).
-
Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study. Ophthalmic Surg Lasers Imaging Retina. 2025 Jul; 56(7):398-406.
-
Quantitative comparison of inner and outer retinal intraretinal hyperreflective foci in age-related macular degeneration. Exp Eye Res. 2025 Jul; 256:110415.
-
Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. Am J Ophthalmol. 2025 Aug; 276:350-364.
-
Clinical Characteristics and Progression of Pachychoroid Macular Atrophy in Central Serous Chorioretinopathy. Ophthalmol Retina. 2025 Oct; 9(10):984-993.
-
Genotypic and Phenotypic Characterization of Hexokinase 1 p.Glu847Lys Variant Causing Autosomal Dominant Pericentral Retinitis Pigmentosa. Ophthalmic Surg Lasers Imaging Retina. 2025 Jun; 56(6):328-334.
-
Sozinibercept Combination Therapy for Neovascular Age-related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type. Ophthalmic Surg Lasers Imaging Retina. 2025 May; 56(5):287-296.